Monitoring methotrexate hepatotoxicity in psoriasis

Indian Journal of Dermatology, Venereology and Leprology

Volumn 77, Issue 5, 2011, Pages 545-548

  Bishnoi, Priya ^a   Kumari, Rashmi ^a   Thappa, Devinder Mohan ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; METHOTREXATE; PROCOLLAGEN; PROCOLLAGEN TYPE 3; UNCLASSIFIED DRUG;

ANOREXIA; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG MONITORING; HUMAN; LIVER BIOPSY; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER INJURY; LIVER TOXICITY; NAUSEA; NONALCOHOLIC FATTY LIVER; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SIDE EFFECT; SUPPLEMENTATION;

DRUG-INDUCED LIVER INJURY; FATTY LIVER; HUMANS; METHOTREXATE; MONITORING, PHYSIOLOGIC; PSORIASIS;

EID: 80052519369     PISSN: 03786323     EISSN: 09733922     Source Type: Journal    
DOI: 10.4103/0378-6323.84014     Document Type: Review

References (17)

1. Roenigk HH Jr, Auerbach R, Maibach HI, Weinstein GD. Methotrexate in psoriasis: Revised guidelines. J Am Acad Dermatol 1988;19:145-56.
2. Haustein UF, Rytter M. Methotrexate in psoriasis: 26 years experience with low-dose long-term treatment. J Eur Acad Dermatol Venereol 2000;14:382-8. (Pubitemid 32898892)
3. Tilling L, Townsend S, David J. Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis. Clin Drug Investig 2006;26:55-62. (Pubitemid 43275699)
4. Gisondi P, Del Giglio M, Cozzi A, Girolomoni G. Psoriasis, the liver, and the gastrointestinal tract. Dermatol Ther 2010;23:155-9.
5. Wenk KS, Arrington KC, Ehrlich A. Psoriasis and non-alcoholic fatty liver disease. J Eur Acad Dermatol Venereol 2011;25:383-91.
6. Langman G, Hall PM, Todd G. Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury. J Gastroenterol Hepatol 2001;16:1395-401. (Pubitemid 34107409)
7. Bangert CA, Costner MI. Methotrexate in dermatology. Dermatol Ther 2007;20:216-28. (Pubitemid 350029311)
8. Paul C, Gallini A, Maza A, Montaudi H, Sbidian E, Aractingi S, et al. Evidence-based recommendations on conventional systemic treatments in psoriasis: Systematic review and expert opinion of a panel of dermatologists. J Eur Acad Dermatol Venereol 2011;25Suppl 2:2-11.
9. Zanolli MD, Sherertz EF, Hedberg AE. Methotrexate: Anti-inflammatory or anti-proliferative? J Am Acad Dermatol 1990;22:523-4.
10. Barker J, Horn EJ, Lebwohl M, Warren RB, Nast A, Rosenberg W, et al. Assessment and management of methotrexate hepatotoxicity in psoriasis patients: Report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. J Eur Acad Dermatol Venereol 2011;25:758-64.
11. Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009;60:824-37.
12. Newman M, Auerbach R, Feiner H, Holzman RS, Shupack J, Migdal P, et al. The role of liver biopsies in psoriatic patients receiving long-term methotrexate treatment. Improvement in liver abnormalities after cessation of treatment. Arch Dermatol 1989;125:1218-24. (Pubitemid 19229051)
13. Zachariae H, Søgaard H. Methotrexate-induced liver cirrhosis. A follow-up. Dermatologica 1987;175:178-82.
14. Chalmers RJ, Kirby B, Smith A, Burrows P, Little R, Horan M, et al. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: A multicentre audit and health economic analysis. Br J Dermatol 2005;152:444-50. (Pubitemid 40547117)
15. Aithal GP, Haugk B, Das S, Card T, Burt AD, Record CO. Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: Are serial liver biopsies justified? Aliment Pharmacol Ther 2004;19:391-9. (Pubitemid 38297107)
16. Smith JO, Sterling RK. Systematic review: Non-invasive methods of fibrosis analysis in chronic hepatitis C. Aliment Pharmacol Ther 2009;30:557-76.
17. Maurice PD, Maddox AJ, Green CA, Tatnall F, Schofield JK, Stott DJ. Monitoring patients on methotrexate: Hepatic fibrosis not seen in patients with normal serum assays of aminoterminal peptide of type III procollagen. Br J Dermatol 2005;152:451-8. (Pubitemid 40547118)